Rodman & Renshaw initiated coverage of Zentalis Pharmaceuticals (NASDAQ: ZNTL) with a “buy” rating and price target of $11.00. The stock closed at $4.50 on July 22.
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, the company aims to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes.
“Azenosertib offers a compelling setup: a biomarker-defined PROC population with no approved targeted therapy and a DENALI Part 2 design that could support accelerated approval if data and FDA dialogue align,” writes Rodman & Renshaw analyst Michael G. King, Jr.
“With DENALI topline expected in YE26, the shares trade ahead of a pivotal readout that can either establish Zentalis as a differentiated ovarian cancer company or return azenosertib to pre-pivotal development,” he adds.
